Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

1(20.0%)

Phase 4

1(20.0%)

5Total

N/A(3)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07384598Not ApplicableNot Yet Recruiting

Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.

Role: lead

NCT06333106Not ApplicableCompleted

PoCUS Diagnostic Accuracy for Fecal Impaction in the Emergency Department: A Prospective Study

Role: collaborator

NCT04982055Phase 4Completed

Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients

Role: lead

NCT04403360Not ApplicableUnknown

Erector Spinae Plane Block After Lumbar Spinal Stenosis Surgery

Role: lead

NCT04401228Unknown

Predictive Models for Intensive Care Admission and Death of COVID-19

Role: lead

NCT00162812Phase 2Terminated

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

Role: collaborator

All 6 trials loaded